In addition, do not use if you have: multiple endocrine neoplasia type 2 (tumors in your glands) a personal or family history of medullary thyroid carcinoma (a type of thyroid cancer) diabetic ketoacidosis (call your doctor for treatment)
Semaglutide 2.4 mg achieved a mean change in body weight from baseline to week 104 of -15.2% in the phase 3b STEP 5 trial, and 77.1% of participants achieved weight loss 5% from baseline at week 104
As employee interest in GLP-1 medications grows, employers may see more questions about insurance coverage, prior authorization, costs, and long-term use
Contextualize heart rate changes within the broader cardiovascular picture
Scand J Med Sci Sports
USP 797 sterile compliance, ISO-classified cleanrooms, PCAB, ACHC, and NABP accreditation, active ingredients from FDA-inspected suppliers, and independent potency and sterility testing on finished preparations